• Current Title: Biotechnology Financing Leader and Innovator
  • Job Field: Pharmaceuticals
  • Years of Experience: 7-11 Years
  • Highest Education: Doctorate
  • Current Career Level: Executive
  • Work Authorization: US Citizen

Lindsay Rosenwald


Lindsay Rosenwald is an American doctor and an expert in investment banking, direct investment, venture capital and asset management within the life sciences and biotechnology industries. He is a co-founder and partner of asset management company Investment Partnership. Under the leadership of Lindsay Rosenwald, the partnership invests in the health-care industry, most notably in biotechnology.

Dr. Lindsay Rosenwald has established numerous biotechnology companies that hold licenses on more than 100 developmental-stage medicines. The U.S. Food and Drug Administration (FDA) and several foreign countries have approved drugs created by companies owned by Lindsay Rosenwald. Notably, Dr. Rosenwald was pivotal in the development of Trisenox (arsenic trioxide), a medicine developed to treat acute promyelocytic leukemia. Trisenox has saved the lives of thousands of people who have been unresponsive to anthracycline chemotherapy.

In 2011, the FDA approved abiraterone acetate, a drug developed in partnership with Lindsay Rosenwald, to treat metastatic castration-resistant prostate cancer after the use of antimitotic chemotherapy medications. In 2012, abiraterone acetate’s, brand name Zytiga, scope of uses was expanded for administration to patients in the pre-chemotherapy stage of treatment. Cougar Biotechnology, the company established by Lindsay Rosenwald to research and develop this drug, was purchased in 2009 for nearly $1 billion by Johnson & Johnson prior to entering Phase III clinical trials.

Dr. Lindsay Rosenwald holds a degree in finance and economics from Pennsylvania State University, where he graduated as a member of the international honor society Beta Gamma Sigma. After two years in the health-care management industry, Dr. Rosenwald enrolled in the Temple University School of Medicine. After obtaining his doctorate in 1983, Dr. Rosenwald entered private medical practice until his focus shifted back to medical-research finance.

In 1988, Lindsay Rosenwald served as managing director of corporate finance for a privately owned health-care investment firm. During his tenure, he oversaw a team of medically trained financiers and led projects to determine the best opportunities and greatest need for private investment in medical research. In 1991, Lindsay Rosenwald established a new biotechnology investment firm, which led to membership in the National Association of Securities Dealers (NASD).

Dr. Rosenwald has received numerous accolades throughout his career including ranking No. 1 in Genetic Engineering News’ 2002 list of “100 Molecular Millionaires.” Rosenwald was previously a member of the board of directors for Keryx Biopharmaceuticals. In 1994, Dr. Rosenwald was asked to serve on the Columbia Presbyterian Health Sciences Advisory Council, a distinction he continues to hold.

Today, Lindsay Rosenwald pours his energy and expertise into Investment Partnership, which he co-founded with a business partner in 2009. He believes that the company’s success is based on its set of core values and its dedication to being a premier investment fund for biotechnology.


Biotechnology Financing Leader and Innovator

Employment History

January 2009 – Present: Co-Founder
Company: Investment Partnership
New York, New York
Co-Founder of Opus Point Partners since 2009.


Temple University School Of Medicine
Temple University School of Medicine , Philadelphia, PA
Graduated: 1983
Grade: MD

Pennsylvania State University
Pennsylvania State University , Philadelphia, PA
Graduated: 1977
Grade: BS